- Home
- HPK vs JANX Comparison
HPK vs JANX Comparison
Compare HPK & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HPK | JANX |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 866.8M | 975.7M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HPK | JANX |
|---|---|---|
| Price | $8.21 | $19.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 13 |
| Target Price | $12.00 | ★ $47.00 |
| AVG Volume (30 Days) | 426.8K | ★ 743.9K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $863,359,000.00 | $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.85 | $12.12 |
| 52 Week High | $9.13 | $35.34 |
Technical Indicators
Market Signals| Indicator | HPK | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 56.70 | 73.46 |
| Support Level | $7.40 | $13.00 |
| Resistance Level | $8.50 | $35.34 |
| Average True Range (ATR) | 0.38 | 0.69 |
| MACD | 0.00 | 0.18 |
| Stochastic Oscillator | 60.86 | 96.52 |
Price Performance
Historical ComparisonAbout HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas exploration and production company that explores for, develops and produces crude oil, NGL, and natural gas prominently in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S. The majority of the company's revenue is derived from the Crude oil sales.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.